Adverse Events of Nucleos(t)ide Analogues for Chronic Hepatitis B: a Systematic Review

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2020 Mar 19

PMID 32185517

Citations 20

Authors

Raquel Scherer de Fraga

Victor Van Vaisberg

Luiz Claudio Alfaia Mendes

Flair Jose Carrilho

Suzane Kioko Ono

Affiliations

Soon will be listed here.

Abstract

Nucleos(t)ide analogues (NAs) are the main drug category used in chronic hepatitis B (CHB) treatment. Despite the fact that NAs have a favourable safety profile, undesired adverse events (AEs) may occur during the treatment of CHB. Given the eminent number of patients currently receiving NAs, even a small risk of any of these toxicities can represent a major medical issue. The main objective of this review was to analyse information available on AEs associated with the use of NAs in published studies. We choose the following MesH terms for this systematic review: chronic hepatitis B, side effects and treatment. All articles published from 1 January 1990 up to 19 February 2018 in MEDLINE of PubMed, EMBASE, the Cochrane Library and LILACS databases were searched. A total of 120 articles were selected for analysis, comprising 6419 patients treated with lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) and 876 with tenofovir alafenamide (TAF). The most common AEs in all NAs assessed were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract infections, fatigue, and headache. TAF displays the highest density of AEs per patient treated among NAs (1.14 AE/treated patient). In conclusion, treatment of CHB with NAs is safe, with a low incidence of AEs. Despite the general understanding TAF being safer than TDF, the number of patients treated with TAF still is too small in comparison to other NAs to consolidate an accurate safety profile. PROSPERO Registration No. CRD42018086471.

Citing Articles

Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.

Sun T, Qiu Y, Wang T, Yang Y, Qiu H, Shen S Cancer Med. 2024; 13(16):e70185.

PMID: 39219190 PMC: 11366777. DOI: 10.1002/cam4.70185.

Short-Term Efficacy of Tenofovir Alafenamide in Acute-On-Chronic Liver Failure: A Single Center Experience.

Li Z, Zhu R, Dong J, Gao Y, Yan J Clin Pathol. 2024; 17:2632010X241265858.

PMID: 39139860 PMC: 11320404. DOI: 10.1177/2632010X241265858.

Patient Preferences and Their Influence on Chronic Hepatitis B-A Review.

Zhang L, Liu Y, Tian J Patient Prefer Adherence. 2023; 17:3119-3124.

PMID: 38053533 PMC: 10695120. DOI: 10.2147/PPA.S433283.

HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis.

Katelani S, Fragoulis G, Bakasis A, Pouliakis A, Nikiphorou E, Atzeni F Rheumatology (Oxford). 2023; 62(SI3):SI252-SI259.

PMID: 37871924 PMC: 10715785. DOI: 10.1093/rheumatology/kead243.

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection.

Akbar S, Al Mahtab M, Yoshida O, Aguilar J, Gerardo G, Hiasa Y Biomedicines. 2023; 11(7).

PMID: 37509583 PMC: 10376977. DOI: 10.3390/biomedicines11071944.

References

Chan H, Heathcote E, Marcellin P, Lai C, Cho M, Moon Y . Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007; 147(11):745-54. DOI: 10.7326/0003-4819-147-11-200712040-00183. View

Fontana R . Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49(5 Suppl):S185-95. DOI: 10.1002/hep.22885. View

Yao G, Zhu M, Cui Z, Wang B, Yao J, Zeng M . A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009; 10(2):131-7. DOI: 10.1111/j.1751-2980.2009.00375.x. View

Perrillo R, Hann H, Schiff E, Mutimer D, Willems B, Leung N . Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011; 5(2):654-63. PMC: 3090563. DOI: 10.1007/s12072-010-9228-9. View

Ali H . Trial of lamivudine in hepatitis B surface antigen carriers with persistent hepatitis B core IgM antibody. Saudi Med J. 2003; 24(9):996-9. View

Ren F, Piao D, Piao X . A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol. 2007; 13(31):4264-7. PMC: 4250629. DOI: 10.3748/wjg.v13.i31.4264. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H . Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 2010; 52(6):791-9. DOI: 10.1016/j.jhep.2009.12.036. View

Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A . Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2010; 60(2):247-54. DOI: 10.1136/gut.2010.223206. View

10.

Gwak G, Eo S, Shin S, Choi M, Lee J, Koh K . A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. Hepatol Int. 2015; 7(1):106-10. DOI: 10.1007/s12072-012-9368-1. View

11.

Martin J, Brown C, Reardon J . Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994; 38(12):2743-9. PMC: 188279. DOI: 10.1128/AAC.38.12.2743. View

12.

Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F . Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol. 2009; 24(2):255-61. DOI: 10.1111/j.1440-1746.2008.05593.x. View

13.

Wang J, He L, Chen Q . Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir. Eur Rev Med Pharmacol Sci. 2013; 17(9):1162-6. View

14.

Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw Y, Cianciara J . Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006; 130(7):2039-49. DOI: 10.1053/j.gastro.2006.04.007. View

15.

Safadi R, Xie Q, Chen Y, Yin Y, Wei L, Hwang S . Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int. 2010; 31(5):667-75. DOI: 10.1111/j.1478-3231.2010.02360.x. View

16.

Lo A, Wong G . Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014; 8(6):607-22. DOI: 10.1586/17474124.2014.909724. View

17.

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

18.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

19.

Lim Y, Yoo B, Byun K, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015; 65(6):1042-51. DOI: 10.1136/gutjnl-2014-308435. View

20.

Imaz A, Podzamczer D . Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther. 2017; 15(3):195-209. DOI: 10.1080/14787210.2017.1286736. View